At a glance
- Originator Faustus Forschungs Compagnie
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in Austria (PO)
- 18 Nov 2005 Preclinical trials in Cancer in Austria (PO)
- 23 Feb 1999 An abstract has been added to the pharmacodynamics section